Anti-cN-1A Ab (NT5c1A) IBM (RDL)
Also known as: Anti-IBM, IBM, Inclusion Body Myopathy, MUP44 AB, nt5c1a
Use
Anti-cN-1A autoantibodies in idiopathic inflammatory myopathy (IIM) patients appear to be disease-specific for sporadic Inclusion Body Myositis (sIBM) and are rarely detected in other autoimmune conditions. Anti-cN-1A autoantibodies have a moderate sensitivity, but their high specificity for sIBM may be helpful in the diagnosis of this infrequent and difficult-to-diagnose myopathy. This assay can augment and accelerate the suspected diagnosis of sIBM using sera where muscle biopsy is delayed and/or unfeasible.
Special Instructions
The assay is beneficial in augmenting and accelerating suspected diagnoses of sIBM, especially when a muscle biopsy is either delayed or not possible.
Limitations
This test was developed and its performance characteristics determined by Labcorp but has not been cleared or approved by the FDA. Hence, it should be interpreted within the clinical context considering this constraint.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 96562-4
- 96562-4
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping.
Storage Instructions
Refrigerate or freeze.
Causes for Rejection
Grossly hemolyzed; bacterial contamination; lipemic specimen; icteric specimen; non-serum specimen types
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |